Janni, W., & Wischnik, A. (2016). Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: Final survival analysis of the ADEBAR study. British journal of cancer, 114(8), . https://doi.org/10.1038/bjc.2016.82
Chicago-Zitierstil (17. Ausg.)Janni, Wolfgang, und Arthur Wischnik. "Randomised Phase III Trial of FEC120 Vs EC-docetaxel in Patients with High-risk Node-positive Primary Breast Cancer: Final Survival Analysis of the ADEBAR Study." British Journal of Cancer 114, no. 8 (2016). https://doi.org/10.1038/bjc.2016.82.
MLA-Zitierstil (9. Ausg.)Janni, Wolfgang, und Arthur Wischnik. "Randomised Phase III Trial of FEC120 Vs EC-docetaxel in Patients with High-risk Node-positive Primary Breast Cancer: Final Survival Analysis of the ADEBAR Study." British Journal of Cancer, vol. 114, no. 8, 2016, https://doi.org/10.1038/bjc.2016.82.